NICE greenlights RoActemra, snubs Afinitor

The U.K.'s cost-effectiveness watchdog changed its mind to recommend Roche's arthritis drug RoActemra for use by the National Health Service, but it rejected the use of Novartis' Afinitor in patients with kidney cancer. Report | Report